Yüksel Ürün
Van Yüzüncü Yıl Üniversitesi · 328 works · 4,147 citations · h-index 26
Top works
- Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
- Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials
- Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
- ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
- Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
- Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
- A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19
- Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
- Survey of the Impact of COVID-19 on Oncologists’ Decision Making in Cancer
- Cytoreductive nephrectomy in patients with metastatic non‐clear‐cell renal cell carcinoma ( RCC )
- Severe drug interactions and potentially inappropriate medication usage in elderly cancer patients
- Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) Versus DHAP (Cytosine Arabinoside-Cisplatin-Dexamethasone) as Salvage Chemotherapy in Patients with Relapsed or Refractory Lymphoma
- Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
- Vaccination in oncology practice and predictors
- Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab
- Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma
- Association of ABO Blood Group and Risk of Lung Cancer in a Multicenter Study in Turkey
- ABO and Rh Blood Groups and Risk of Colorectal Adenocarcinoma